216 related articles for article (PubMed ID: 37183261)
1. CRISPR-cas9 screening identified lethal genes enriched in Hippo kinase pathway and of predictive significance in primary low-grade glioma.
Mijiti M; Maimaiti A; Chen X; Tuersun M; Dilixiati M; Dilixiati Y; Zhu G; Wu H; Li Y; Turhon M; Abulaiti A; Maimaitiaili N; Yiming N; Kasimu M; Wang Y
Mol Med; 2023 May; 29(1):64. PubMed ID: 37183261
[TBL] [Abstract][Full Text] [Related]
2. CRISPR-cas9 Screening Identified Lethal Genes Enriched in Cell Cycle Pathway and of Prognosis Significance in Breast Cancer.
Sun X; Wang Z; Chen X; Shen K
Front Cell Dev Biol; 2021; 9():646774. PubMed ID: 33816496
[TBL] [Abstract][Full Text] [Related]
3. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
[TBL] [Abstract][Full Text] [Related]
4. Screening and identification of CNIH4 gene associated with cell proliferation in gastric cancer based on a large-scale CRISPR-Cas9 screening database DepMap.
Zhang H; Lin Y; Zhuang M; Zhu L; Dai Y; Lin M
Gene; 2023 Jan; 850():146961. PubMed ID: 36220450
[TBL] [Abstract][Full Text] [Related]
5. CRISPR-Cas9 screening identified lethal genes enriched in necroptosis pathway and of prognosis significance in osteosarcoma.
Cheng L; Xiong W; Li S; Wang G; Zhou J; Li H
J Gene Med; 2023 Dec; 25(12):e3563. PubMed ID: 37421290
[TBL] [Abstract][Full Text] [Related]
6. Development and Verification of Glutamatergic Synapse-Associated Prognosis Signature for Lower-Grade Gliomas.
Ye L; Xu Y; Hu P; Wang L; Yang J; Yuan F; Wang Y; Zhang C; Tian D; Chen Q
Front Mol Neurosci; 2021; 14():720899. PubMed ID: 34776862
[No Abstract] [Full Text] [Related]
7. Identification of UBE2I as a Novel Biomarker in ccRCC Based on a Large-Scale CRISPR-Cas9 Screening Database and Immunohistochemistry.
Li F; Lai L; You Z; Cheng H; Guo G; Tang C; Xu L; Liu H; Zhong W; Lin Y; Wang Q; Lin Y; Wei Y
Front Mol Biosci; 2022; 9():813428. PubMed ID: 35211510
[No Abstract] [Full Text] [Related]
8. A Novel 10-Gene Signature Predicts Poor Prognosis in Low Grade Glioma.
Liu W; Zou J; Ren R; Liu J; Zhang G; Wang M
Technol Cancer Res Treat; 2021; 20():1533033821992084. PubMed ID: 33550903
[TBL] [Abstract][Full Text] [Related]
9. Identification and validation of a three-gene signature as a candidate prognostic biomarker for lower grade glioma.
Xiao K; Liu Q; Peng G; Su J; Qin CY; Wang XY
PeerJ; 2020; 8():e8312. PubMed ID: 31921517
[TBL] [Abstract][Full Text] [Related]
10. Use of Genome-Scale Integrated Analysis to Identify Key Genes and Potential Molecular Mechanisms in Recurrence of Lower-Grade Brain Glioma.
Deng T; Gong YZ; Wang XK; Liao XW; Huang KT; Zhu GZ; Chen HN; Guo FZ; Mo LG; Li LQ
Med Sci Monit; 2019 May; 25():3716-3727. PubMed ID: 31104065
[TBL] [Abstract][Full Text] [Related]
11. Identification and Validation of an Energy Metabolism-Related lncRNA-mRNA Signature for Lower-Grade Glioma.
Zhao J; Wang L; Wei B
Biomed Res Int; 2020; 2020():3708231. PubMed ID: 32802843
[TBL] [Abstract][Full Text] [Related]
12. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
Front Immunol; 2022; 13():899710. PubMed ID: 35677036
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of γ-aminobutyric acidergic synapse-associated signature for lower-grade gliomas.
Jiang H; Sun Z; Li F; Chen Q
Front Immunol; 2022; 13():983569. PubMed ID: 36405708
[TBL] [Abstract][Full Text] [Related]
14. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
[TBL] [Abstract][Full Text] [Related]
15. Screening TCGA database for prognostic genes in lower grade glioma microenvironment.
Ni J; Liu S; Qi F; Li X; Yu S; Feng J; Zheng Y
Ann Transl Med; 2020 Mar; 8(5):209. PubMed ID: 32309356
[TBL] [Abstract][Full Text] [Related]
16. Validation of the functions and prognostic values of synapse-associated proteins in lower-grade glioma.
Lin H; Yang Y; Hou C; Huang Y; Zhou L; Zheng J; Lv G; Mao R; Chen S; Xu P; Zhou Y; Wang P; Zhou D
Biosci Rep; 2021 May; 41(5):. PubMed ID: 33969375
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia-Related lncRNA Correlates With Prognosis and Immune Microenvironment in Lower-Grade Glioma.
Xu S; Tang L; Liu Z; Luo C; Cheng Q
Front Immunol; 2021; 12():731048. PubMed ID: 34659218
[TBL] [Abstract][Full Text] [Related]
18. Identification of LARS as an essential gene for osteosarcoma proliferation through large-Scale CRISPR-Cas9 screening database and experimental verification.
Chen W; Lin Y; Jiang M; Wang Q; Shu Q
J Transl Med; 2022 Aug; 20(1):355. PubMed ID: 35962451
[TBL] [Abstract][Full Text] [Related]
19. Systematic transcriptome profiling of pyroptosis related signature for predicting prognosis and immune landscape in lower grade glioma.
Yu H; Gong M; Qi J; Zhao C; Niu W; Sun S; Li S; Hong B; Qian J; Wang H; Chen X; Fang Z
BMC Cancer; 2022 Aug; 22(1):885. PubMed ID: 35964070
[TBL] [Abstract][Full Text] [Related]
20. A Computational Framework to Identify Biomarkers for Glioma Recurrence and Potential Drugs Targeting Them.
Ma S; Guo Z; Wang B; Yang M; Yuan X; Ji B; Wu Y; Chen S
Front Genet; 2021; 12():832627. PubMed ID: 35116059
[No Abstract] [Full Text] [Related]
[Next] [New Search]
